Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(17):1181-1182; doi:10.1093/jnci/djj384
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Bankhead, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bankhead, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

NEWS

Three New Drugs Available To Fight Kidney Cancer

Charles Bankhead

The first 10% of the full text of this article appears below.

More help could be on the way for the battle against renal cell carcinoma (RCC). Three new therapies showed promise in recent reports from the American Society of Clinical Oncology annual meeting. The benefits ranged from modest in a specific group of patients to potentially dramatic, which led the investigator to proclaim that a new standard of care has emerged.

The most impressive results came from a randomized trial comparing sunitinib to standard therapy with interferon-{alpha} in patients with metastatic RCC. Treatment with sunitinib led to a doubling of progression-free survival compared with the interferon group and a fivefold greater response rate.

"Sunitinib is the . . . [Full Text of this Article]

Other New Options


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?